Search results
Results from the WOW.Com Content Network
Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. [3][4][8] It appears to result in a small benefit in mental function and ability to function. [9] Use, however, has not been shown to change the progression of the disease. [10]
Medical condition Dementia with Lewy bodies Other names Diffuse Lewy body disease, dementia due to Lewy body disease Microscopic image of a Lewy body (arrowhead) in a neuron of the substantia nigra ; scale bar=20 microns (0.02 mm) Specialty Neurology, psychiatry Symptoms Dementia, abnormal behavior during REM sleep, fluctuations in alertness, visual hallucinations, parkinsonism Usual onset ...
Cerebrolysin (developmental code name FPF-1070) is an experimental mixture of enzymatically -treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). [ 3 ][ 4 ] Although ...
Some drugs used to treat type 2 diabetes could also help lower a person’s risk of neurodegenerative diseases, such as Alzheimer’s. Image credit: martin-dm/Getty Images.
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, [ 2 ] and is the cause of 60–70% of cases of dementia. [ 2 ][ 15 ] The most common early symptom is difficulty in remembering recent events. [ 1 ] As the disease advances, symptoms can include problems with language, disorientation ...
AFib, the most common heart rhythm disorder, is linked to a 39% increased risk of cognitive impairment, while coronary heart disease increases the risk of dementia by 27%, with up to 50% of heart ...
Researchers found that patients with musical hallucinations respond well to the drug Donepezil, making it another potential treatment for the condition. Donepezil, which belongs to a class of medication called acetylcholinesterase inhibitors , is most commonly used to treat dementia in patients with Alzheimer's disease.
Sugimoto was born as the eighth child among nine children in a downtown section of Tokyo in 1943, and joined Eisai, a Japanese pharmaceutical company. [3] While working for Eisai, he graduated from Chuo University in 1969 and obtained his doctorate in pharmacology at Hiroshima University in 2002. [3] In 2003, he retired from Eisai, and became ...